LivaNova Presents New Data at European Association for Cardio-Thoracic Surgery Annual Meeting Demonstrating Benefits of Perceval Sutureless Valve
LivaNova PLC (NASDAQ:LIVN) a market-leading medical technology and innovation company, today announced new data from the Perceval® Sutureless Implant Versus Standard-Aortic Valve Replacement (PERSIST-AVR) clinical study and the Sorin Universal Registry on Aortic Valve Replacement (SURE-AVR). Results from a PERSIST-AVR sub-analysis demonstrated better clinical outcomes for patients with aortic valve stenosis who received the Perceval sutureless surgical aortic valve via minimally invasive cardiac surgery (MICS) than patients who received a stented valve through the same access. Data from a SURE-AVR sub-analysis further supported positive findings for Perceval using MICS or full sternotomy. The results were presented during a series of presentations at the 34th Annual Meeting of the European Association for Cardio-Thoracic Surgery (EACTS).
“The new PERSIST-AVR data presented at EACTS highlight that the Perceval valve is a reliable and essential technology to be considered as part of any comprehensive valve program and an essential complement to transcatheter technology. Due to its innovative sutureless design, Perceval facilitates minimally invasive cardiac surgery and offers these patients significant benefits such as decreased procedure times, fewer complications and fewer re-hospitalizations,” said Dr. Brian Duncan, Vice President of Medical Affairs at LivaNova. “New findings from SURE-AVR presented at EACTS further demonstrate important benefits from innovation in our next-generation Perceval Plus valve resulting in improved patient outcomes.”
PERSIST-AVR Clinical Study
The prospective, randomized, multi-center, international PERSIST-AVR study assessed the safety, efficacy and noninferiority of the sutureless Perceval valve compared with standard stented bio-prostheses using conventional or mini-sternotomy. A total of 910 patients with severe symptomatic aortic valve stenosis were enrolled in 12 countries. A total of 578 patients underwent isolated aortic valve replacement (AVR).
PERSIST-AVR results presented during EACTS showed that patients who received Perceval during a mini-sternotomy in isolated AVR had a significantly lower incidence of:
- Major adverse cardiovascular and cerebrovascular events (MACCEs) – 5.2% of the Perceval group versus 10.8% of the stented valve group
- New onset of atrial fibrillation – 4.2% in the Perceval group versus 11.4% in the stented valve group
- Stroke – 1% in the Perceval group versus 5.4% in the stented valve group
Prof. Roberto Lorusso, Full Professor in the Cardio-Thoracic Surgery Department of the Maastricht University Medical Centre, the Netherlands, presented the new PERSIST-AVR data. “In this sub-cohort, Perceval significantly reduced MACCEs at one-year follow up, reduced re-hospitalization days and demonstrated a 30% reduction in cross-clamping time, providing patients with a minimally invasive and less traumatic surgical solution compared to stented valves,” said Prof. Lorusso. “This data is encouraging as it provides further evidence that Perceval facilitates MICS and simplifies complex procedures when time matters.”
The ongoing, prospective, international SURE-AVR registry used real-world data to compare outcomes of patients who received Perceval using MICS or conventional full sternotomy. SURE-AVR is collecting data on outcomes from patients at 60 sites in 18 countries. One sub-analysis presented at EACTS was based on data from 980 isolated AVR patients at 52 international institutions. A total of 676 patients underwent MICS and 304 received a full sternotomy. Results showed that Perceval enables MICS, providing a rate of successful implantation similar to that of full sternotomy.
Dr. Marco Solinas, Cardiac Surgeon, G. Monasterio Foundation Heart Hospital, Massa, Italy, presented the SURE-AVR registry data at EACTS. “These real-life results from an international registry showed that implanting Perceval during MICS resulted in significantly shorter ICU stays than a complete sternotomy and that Perceval in isolated AVR is associated with early- and mid-term good clinical and hemodynamic results both in MICS and full sternotomy,” said Dr. Solinas. “Furthermore, Perceval in MICS results in comparable cross-clamping time to full-sternotomy, eliminating the main concern for broader MICS adoption and reinforcing the role of Perceval as a MICS enabler.”
Analysis of the SURE-AVR registry also provided initial real-world clinical performance data of the Perceval Plus™ valve. Perceval Plus is designed to enhance the Perceval platform by decreasing permanent pacemaker implantation (PPI) rates and improving durability, further advancing the treatment of aortic valve stenosis. Of patients enrolled in SURE-AVR between March 2011 and February 2020, 1,374 underwent AVR with the Perceval valve and 121 with the Perceval Plus valve.
PD Dr. Maximilian Scherner, Department of Cardiac and Thoracic Surgery, University Hospital Magdeburg, Germany, presented data from SURE-AVR related to Perceval Plus during EACTS. “Perceval Plus further improved patient outcomes with reduced pacemaker implantation rates compared to Perceval, while both valves were associated with overall low morbidity and mortality,” said PD Dr. Scherner. “Changes to the design did not impact the sealing at the annulus, and both Perceval and Perceval Plus demonstrated a low percentage of paravalvular regurgitation.”
LivaNova received CE Mark for Perceval in 2011 followed by U.S. Food and Drug Administration approval in 2016. The company received CE Mark for Perceval Plus in 2018. To date, more than 50,000 patients worldwide have been treated with the Perceval valve. To learn more about Perceval and Perceval Plus, visit www.livanova.com.
LivaNova PLC is a global medical technology and innovation company built on nearly five decades of experience and a relentless commitment to provide hope for patients and their families through innovative medical technologies, delivering life-changing improvements for both the Head and Heart. Headquartered in London, LivaNova employs approximately 4,000 employees and has a presence in more than 100 countries for the benefit of patients, healthcare professionals and healthcare systems worldwide. LivaNova operates as two businesses: Cardiovascular and Neuromodulation, with operating headquarters in Mirandola (Italy) and Houston (U.S.), respectively.
For more information, please visit www.livanova.com.
Safe Harbor Statement
This news release contains “forward-looking statements” concerning our goals, beliefs, expectations, strategies, objectives, plans and underlying assumptions and other statements that are not necessarily based on historical facts. These statements include, but are not limited to, statements regarding Perceval, Perceval Plus and findings from the PERSIST-AVR clinical study and SURE-AVR registry. Actual results may differ materially from those indicated in our forward-looking statements as a result of various factors, including those factors set forth in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2019, as supplemented by any risk factors contained in our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. We undertake no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.
LivaNova PLC Media Contact
Deanna Wilke, +1 (281) 727-2764
VP, Corporate Communications
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Data from the APOLLO Study Show Clinically Meaningful Response with DARZALEX ® ▼ (daratumumab) Subcutaneous Formulation Regimen After First or Subsequent Relapse in Multiple Myeloma4.12.2020 20:52:00 CET | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson announced results of the Phase 3 APOLLO study showing that the addition of DARZALEX®▼ (daratumumab) subcutaneous (SC) formulation to pomalidomide and dexamethasone (D-Pd) significantly reduced the risk of progression or death by 37 percent, compared to Pd alone in patients with multiple myeloma (MM) after the first or subsequent relapse of disease.1 The APOLLO results, which will be presented on Sunday, December 6 at 9:00 p.m. CET during the American Society of Hematology (ASH) 2020 Annual Meeting and featured in the ASH press briefing (Abstract #112), add to the body of evidence supporting treatment with daratumumab SC-based regimens for patients with relapsed MM. These data were the basis for recent regulatory submissions in Europe and the United States (U.S.) seeking approval for daratumumab SC in combination with Pd for the treatment of patients with relapsed or refractory MM, with two or more prior lines of therapy, includi
Citi Private Bank Issues Outlook 2021: The New Economic Cycle: Investing for a Post-COVID World4.12.2020 17:36:00 CET | Press release
Citi Private Bank has released its Outlook 2021: The New Economic Cycle: Investing for a Post-COVID World. The twice-yearly publication provides in-depth insights into the global economy and financial markets for the coming year and highlights multi-year “unstoppable trends” for client portfolios. This edition outlines why this is a remarkable time to be an investor. Just as the pandemic changed the price of every security when it arrived, the departure of COVID will mark the beginning of a new economic cycle, creating new opportunities for investors. Citi Private Bank expects 2021 will benefit from an economy that demonstrated resilience in the face of the worst global healthcare crisis in more than a century. 2020 was an opportunity for the world to “test drive the future” and make way for growth as the pandemic ebbs. The tailwinds for 2021 are underappreciated: our financial system is strong, government actions to protect individuals and businesses have been effective, technological
Takashi Nagao Appointed President and Chief Executive Officer of Medicago4.12.2020 17:00:00 CET | Press release
Medicago, a biopharmaceutical company headquartered in Quebec City, Canada, today announced Takashi Nagao as the company’s new President and Chief Executive Officer. Prior to becoming President and CEO, Mr. Nagao served as the Chairman of the Board of Medicago, where for the last four years, he has guided Medicago executives to get the company to where it is today. Medicago, a research and development company for the last 20 years, is embarking on a transformative year, one that will see the company build on its R&D roots to become a company that also produces and commercializes vaccines and other immunotherapies. Mr. Nagao has extensive experience leading pharmaceutical companies through the pre-commercial and commercial process and is well positioned to ensure the successful launch of Medicago’s COVID-19 and influenza vaccines, subject to regulatory approvals. Mr. Nagao will continue Medicago’s evolution towards its goal of being a fully operational commercial entity, able to respond
WorldRemit Leads the Way Offering a USD Payout Option in Nigeria4.12.2020 16:46:00 CET | Press release
WorldRemit, a leading digital cross-border payments business has announced that its customers in Nigeria can now receive remittances in foreign currency (USD) through its cash pick up providers. Following the announcement of the Central Bank of Nigeria (CBN) a day before, WorldRemit quickly adapted to the new requirements making it the first digital service to offer its customers worldwide the option of cash pickup in USD in Nigeria. WorldRemit enables Nigerians in over 50 countries around the world to support their family and friends in Nigeria. The decision by the Central Bank of Nigeria (CBN) to allow international money transfers to be paid in foreign currency, is aimed at providing increased liquidity in the foreign exchange market. The bank explained that the new regulation is part of its efforts to liberalize, simplify and improve the receipt and administration of diaspora remittances into Nigeria. Gbenga Okejimi, Country Manager, Nigeria and Ghana, at WorldRemit, said:“ We are
PPC Upgraded to ‘B’ with ‘Stable’ Outlook by S&P4.12.2020 15:16:00 CET | Press release
In its annual research update released on 27 November 2020, S&P upgraded PPC’s stand-alone credit profile (SACP) upward by two notches to ‘B’ from ‘CCC+’, resulting in an overall upgrade of the long-term credit rating of PPC to ‘B’ from ‘B-‘. According to S&P the two notch upgrade in PPC’s standalone corporate rating confirms that the Company’s strategic repositioning and the improved Greek energy market fundamentals have transformed its competitive position, reducing past concerns over its liquidity and long-term sustainability. The ‘Stable’ outlook underscores S&P’s expectation that PPC will continue to deliver on its transformation plan, with solid liquidity and improved margins. PPC’s strategic plan to convert its generation mix toward lower carbon dioxide (CO2) emissions improve its fleet competitiveness and long-term prospects. As mentioned in their report, S&P expects a substantial increase in EBITDA and improvement in credit metrics on the back of higher profitability as PPC ac
Chengdu Launches Online Exhibition of History and Culture to Enhance Cultural Ties With European Countries4.12.2020 13:17:00 CET | Press release
The launching ceremony of Chengdu History and Culture Overseas Virtual Exhibition was held by the Chengdu Chronicles Compilation Committee at Chengdu Chronicles Office on 24 November. The event, along with the unveiling ceremony of Chengdu Chronicles Culture Overseas (Europe) Exchange Cooperation, were witnessed by distinguished guests in many European countries including the Netherlands, Germany and Belgium through video and online connections. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201204005278/en/ On November 24, Gao Zhigang (center), Director of Chengdu Chronicles Compilation Committee at Chengdu Chronicles Office, and other guests attend the launching ceremony of Chengdu History and Culture Overseas Virtual Exhibition. (Photo: Business Wire) Chengdu History and Culture Overseas Virtual Exhibition will also be launched at major foreign media platforms for audiences all over the world. Gao ZhiGang, Director of Che
New Phase 3 Data Show TAK-620 (maribavir), an Investigational Drug for the Treatment of Transplant Recipients with Refractory/Resistant Cytomegalovirus (CMV) Infections, Meets Primary Endpoint4.12.2020 12:00:00 CET | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced top-line results from the Phase 3 clinical trial evaluating the efficacy and safety of the investigational drug TAK-620 (maribavir), in the treatment of transplant recipients with refractory/resistant cytomegalovirus (CMV) infection. The TAK-620-303 (SOLSTICE) trial (NCT02931539) is a multicenter, randomized, open-label, active-controlled trial comparing eight weeks of treatment with either maribavir or investigator assigned treatment (IAT) in transplant recipients with CMV infection refractory or resistant to existing antiviral treatments (i.e., one or a combination of ganciclovir, valganciclovir, foscarnet or cidofovir). The SOLSTICE trial met its primary endpoint, defined as the proportion of patients who achieved confirmed CMV viremia clearance compared to IAT at the end of Study week 8. In addition, the SOLSTICE trial met its key secondary endpoint, defined as achievement of CMV viremia clearance